Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw an uptick in trading volume on Tuesday . 41,187 shares changed hands during trading, an increase of 13% from the previous session’s volume of 36,334 shares.The stock last traded at $40.4970 and had previously closed at $40.13.

Analyst Ratings Changes

NBTX has been the subject of a number of analyst reports. TD Cowen began coverage on Nanobiotix in a report on Friday, February 6th. They issued a “buy” rating for the company. Leerink Partners reissued an “outperform” rating on shares of Nanobiotix in a report on Tuesday, November 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, Guggenheim upped their price target on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Nanobiotix Trading Down 3.6%

The company has a fifty day moving average price of $24.25 and a 200 day moving average price of $20.56.

Institutional Trading of Nanobiotix

Institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC bought a new position in shares of Nanobiotix during the fourth quarter valued at about $390,000. Marshall Wace LLP purchased a new stake in Nanobiotix during the 4th quarter valued at about $220,000. Optiver Holding B.V. purchased a new stake in Nanobiotix during the 3rd quarter valued at about $101,000. Finally, Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after acquiring an additional 2,500 shares during the last quarter. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.